Puerto Rican plant to boost US supplies of heparin
This article was originally published in Scrip
Executive Summary
US FDAapproval for APP Pharmaceuticals's Puerto Rican plant to manufacture three heparin products should help ensure the uninterrupted and safe supply of heparin to the US, says the company. APP is currently the sole supplier of therapeutic heparin vials to the US after contamination problems occurred there earlier this year, says the company's CEO, Tom Silberg. Nine products are currently manufactured at the company's Puerto Rican plant, including doxycycline, azithromycin and diphenhydramine.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.